Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Statistical Methods in Medical Research|June 3, 2017
Estimating age-specific reproductive numbers-A comparison of methodsCarlee B Moser, Laura F White
American Journal of Epidemiology|October 9, 2020
Statistical Estimation of the Reproductive Number From Case Notification DataLaura F White, Carlee B Moser, Robin N Thompson, et al.
Plos One|March 21, 2015
The impact of prior information on estimates of disease transmissibility using Bayesian toolsCarlee B Moser, Mayetri Gupta, Brett N Archer, et al.
Iscience|May 30, 2024
Machine learning models based on fluid immunoproteins that predict non-AIDS adverse events in people with HIVThomas A Premeaux, Scott Bowler, Courtney M Friday, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 14, 2018
Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260sTheodoros Kelesidis, Carlee B Moser, Elizabeth Johnston, et al.
Circulation. Arrhythmia and Electrophysiology|March 11, 2014
Association of sex hormones, aging, and atrial fibrillation in men: the Framingham Heart StudyJared W Magnani, Carlee B Moser, Joanne M Murabito, et al.
AIDS (London, England)|August 9, 2021
Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapyThomas A Premeaux, Carlee B Moser, Ashley McKhann, et al.
American Heart Journal|April 24, 2012
Age of natural menopause and atrial fibrillation: the Framingham Heart StudyJared W Magnani, Carlee B Moser, Joanne M Murabito, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 13, 2018
Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral SuppressionMartin Hoenigl, Carlee B Moser, Nicholas Funderburg, et al.
The Journal of Infectious Diseases|August 31, 2023
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 TrialCarlee B Moser, Kara W Chew, Justin Ritz, et al.
Pageof 3